Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer

Lodewijk, Iris ; Rubio, Carolina ; Eriksson, Pontus LU ; Reina, Ignacio A. ; Montesinos, Esther ; Alonso-Sánchez, Miguel ; García-Gómez, Laura ; Martín de Bernardo, Álvaro ; Morales, Lucía and Suárez-Cabrera, Cristian , et al. (2026) In Scientific Reports 16(1).
Abstract

Bladder cancer is a fast-moving and recurrent malignancy where survival hinges on early detection and precise risk stratification. The search for robust biomarkers is urgent, and CD44v6 has emerged as a compelling candidate. In this study, we explored the clinical and functional associations of CD44v6 expression in bladder cancer. Integrated analyses of patient samples and cell lines showed that high CD44v6 expression is strongly associated with poor patient outcomes, enhanced migratory and invasive behavior, and increased resistance to cisplatin. These results suggest that CD44v6 may serve as a prognostic biomarker and a potential therapeutic target in bladder cancer. Overall, our findings highlight the translational relevance of... (More)

Bladder cancer is a fast-moving and recurrent malignancy where survival hinges on early detection and precise risk stratification. The search for robust biomarkers is urgent, and CD44v6 has emerged as a compelling candidate. In this study, we explored the clinical and functional associations of CD44v6 expression in bladder cancer. Integrated analyses of patient samples and cell lines showed that high CD44v6 expression is strongly associated with poor patient outcomes, enhanced migratory and invasive behavior, and increased resistance to cisplatin. These results suggest that CD44v6 may serve as a prognostic biomarker and a potential therapeutic target in bladder cancer. Overall, our findings highlight the translational relevance of CD44v6 and provide a foundation for future studies aimed at elucidating the mechanistic pathways underlying its role in tumor aggressiveness and chemoresistance.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
CD44v6, Prognosis, TAA, Targeted therapy, Urothelial Cancer
in
Scientific Reports
volume
16
issue
1
article number
13108
publisher
Nature Publishing Group
external identifiers
  • pmid:41813784
  • scopus:105036550605
ISSN
2045-2322
DOI
10.1038/s41598-026-42566-0
language
English
LU publication?
yes
id
b28392b6-09f8-4fdd-80b7-1d494f95ecf1
date added to LUP
2026-05-29 13:15:03
date last changed
2026-08-23 02:23:36
@article{b28392b6-09f8-4fdd-80b7-1d494f95ecf1,
  abstract     = {{<p>Bladder cancer is a fast-moving and recurrent malignancy where survival hinges on early detection and precise risk stratification. The search for robust biomarkers is urgent, and CD44v6 has emerged as a compelling candidate. In this study, we explored the clinical and functional associations of CD44v6 expression in bladder cancer. Integrated analyses of patient samples and cell lines showed that high CD44v6 expression is strongly associated with poor patient outcomes, enhanced migratory and invasive behavior, and increased resistance to cisplatin. These results suggest that CD44v6 may serve as a prognostic biomarker and a potential therapeutic target in bladder cancer. Overall, our findings highlight the translational relevance of CD44v6 and provide a foundation for future studies aimed at elucidating the mechanistic pathways underlying its role in tumor aggressiveness and chemoresistance.</p>}},
  author       = {{Lodewijk, Iris and Rubio, Carolina and Eriksson, Pontus and Reina, Ignacio A. and Montesinos, Esther and Alonso-Sánchez, Miguel and García-Gómez, Laura and Martín de Bernardo, Álvaro and Morales, Lucía and Suárez-Cabrera, Cristian and Pérez-Escavy, Mercedes and Alberquilla, Omaira and Sánchez-Domínguez, Rebeca and Guerrero-Ramos, Félix and García-Martin, Rosa and Parrilla, Lucía and Rodríguez-Peralto, José L. and Castellano, Daniel and Paramio, Jesús M. and Sjödahl, Gottfrid and Dueñas, Marta}},
  issn         = {{2045-2322}},
  keywords     = {{CD44v6; Prognosis; TAA; Targeted therapy; Urothelial Cancer}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Scientific Reports}},
  title        = {{CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer}},
  url          = {{http://dx.doi.org/10.1038/s41598-026-42566-0}},
  doi          = {{10.1038/s41598-026-42566-0}},
  volume       = {{16}},
  year         = {{2026}},
}